Inari Medical, Inc. (NASDAQ: NARI) reported Q3 EPS of ($0.31), $0.19 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $153 million versus the consensus estimate of $150.69 million.

GUIDANCE:

Inari Medical, Inc. sees FY2024 revenue of $601.5-604.5 million, versus the consensus of $600 million, an increase of $3.5 million at the midpoint from our prior guidance range of $594.5 million to $604.5 million, reflecting growth of approximately 21.9% to 22.5% over 2023.
The company continues to expect to reach sustained operating profitability in the first half of 2025.

For earnings history and earnings-related data on Inari Medical, Inc. (NARI) click here.